Dermatitis Research Today is a free monthly online journal that collates and summarizes the latest research about Dermatitis, including details on contact-, seborrheic-, atopic-, allergic-dermatitis, treatment.

Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.

Ziemer M, Wiesend CL, Vetter R, Weiss J, Blaschke S, Norgauer J, Mockenhaupt M

Department of Dermatology, University of Jena, Erfurter Strasse 35, D-07743 Jena, Germany. mirjana.ziemer@derma.uni-jena.de

OBJECTIVE: To assess the type of severe skin reactions caused by valdecoxib treatment. DESIGN: Case registry of severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. SETTING: All hospitals in Germany that treat patients with severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. PATIENTS: Five case notifications of Stevens-Johnson syndrome after the use of valdecoxib were reevaluated following the withdrawal of valdecoxib on April 7, 2005. RESULTS: A thorough review of all reported cases of severe skin reactions caused by valdecoxib revealed extensive erythematous, targetlike skin eruptions in addition to facial edema and dyspnea. Histologic changes, clinical pattern, and outcome demonstrated a distinct disease entity. CONCLUSION: Valdecoxib induces severe skin reactions different from those of Stevens-Johnson syndrome and toxic epidermal necrolysis in clinical and histopathologic findings, course, and outcome.

Published 19 June 2007 in Arch Dermatol, 143(6): 711-6.
Full-text of this article is available online (may require subscription).

© 2004-2008 Dermatitis Research Today. All Rights Reserved.